Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose, dose escalation study of LY2439821 in Japanese patients with rheumatoid arthritis on methotrexate
jRCT2080221108Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ixekizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability of multiple subcutaneous doses of LY2439821, Pharmacokinetics of LY2439821 and 1 more.
02
Drugs
ixekizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221108.